Latest Profitability News

BKI Investment Company Limited reported a modest rise in ordinary revenue and declared a 1% higher interim dividend despite a challenging economic backdrop and softer special investment income.

BKI Investment Company Limited has announced a fully franked ordinary dividend of AUD 0.039 per share for the half-year ending December 31, 2024, payable on February 28, 2025. The company’s Dividend Reinvestment Plan remains active, offering shareholders flexibility.

BKI Investment Company Limited posted a decline in net profit and earnings per share for the half-year ending December 31, 2024, yet declared a higher fully franked interim dividend, signaling confidence amid economic headwinds.

New Frontier Minerals has entered a strategic alliance with Austral Resources to process copper ore from its Big One Deposit, aiming to accelerate production and exploration in the Mt Isa copper belt.

Ava Risk Group reports a 20% revenue increase in H1 FY2025, driven by robust sales order intake and strategic expansion in key security sectors.

Qoria Limited reports robust December quarter results for FY2025, driven by strong ARR growth, expanding global reach, and strategic AI innovations that promise to accelerate future growth.

Activeport has successfully closed a $6.1 million capital raise, including a significant placement to new institutional investor MWP Partners, positioning the company for accelerated growth in the global telecommunications and data centre software markets.

Aumake Limited has inked a two-year e-commerce collaboration with Sichuan Airlines, opening access to over 30 million passengers annually and initiating sales with a AU$281,361 purchase order of premium Australian alcohol.

Korvest Ltd has announced a fully franked ordinary dividend of AUD 0.25 per share for the six months ending December 2024, signaling steady shareholder returns.

Korvest Ltd reported a 1.1% decline in revenue and a sharp 28.5% drop in net profit for the half-year ending December 2024, impacted by operational disruptions and competitive pressures. Despite these challenges, the company anticipates a robust rebound in project activity in the second half of FY25.

PolyNovo Limited reports a robust 22.8% revenue increase in 1H FY25, driven by strong U.S. and international sales growth and progressing FDA approval efforts for its NovoSorb platform.

Immuron Limited reports a striking 70% quarter-on-quarter increase in Travelan® sales, driven by expanded pharmacy distribution in Australia and North America.